MISSIONPHARMA A/S — Credit Rating and Financial Key Figures
CVR number: 26902398
Vassingerødvej 9, 3540 Lynge
info@missionpharma.com
tel: 48163248
Income statement (mDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 776.98 | 731.47 | 693.96 | 924.32 | 928.80 |
| Costs of manufacturing | - 398.28 | - 571.60 | - 545.38 | ||
| External services | - 173.42 | - 123.38 | - 163.46 | ||
| Gross profit | 81.53 | 171.93 | 122.25 | 229.34 | 219.96 |
| Employee benefit expenses | -48.34 | -65.44 | -65.69 | ||
| Other operating expenses | -0.70 | ||||
| Total depreciation | -1.59 | -4.30 | -2.93 | ||
| EBIT | 81.53 | 171.93 | 71.63 | 159.60 | 151.34 |
| Other financial income | 0.21 | 3.93 | 6.00 | ||
| Other financial expenses | -0.84 | -9.13 | -3.46 | ||
| Net income from associates (fin.) | 2.67 | ||||
| Pre-tax profit | 22.24 | 83.61 | 73.67 | 154.40 | 153.88 |
| Income taxes | -15.69 | -35.14 | -34.13 | ||
| Net earnings | 22.24 | 83.61 | 57.98 | 119.26 | 119.75 |
Assets (mDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Development expenditure | 1.29 | ||||
| Intangible assets total | 1.29 | ||||
| Land and waters | 22.51 | 24.90 | 23.88 | ||
| Buildings | 1.19 | 4.82 | 6.13 | ||
| Tangible assets total | 23.71 | 29.72 | 30.01 | ||
| Participating interests | 33.20 | ||||
| Other non-current investments | 18.42 | 18.29 | |||
| Other receivables | 380.97 | 427.21 | |||
| Investments total | 380.97 | 427.21 | 33.20 | 18.42 | 18.29 |
| Non-current loans receivable | 0.44 | 2.19 | |||
| Long term receivables total | 0.44 | 2.19 | |||
| Finished products/goods | 32.46 | 111.48 | 125.30 | ||
| Inventories total | 32.46 | 111.48 | 125.30 | ||
| Current trade debtors | 35.72 | 62.23 | 57.66 | ||
| Current amounts owed by group member comp. | 262.50 | 212.39 | 153.46 | ||
| Prepayments and accrued income | 20.61 | 73.61 | 22.20 | ||
| Current other receivables | 9.04 | 4.56 | 6.07 | ||
| Current deferred tax assets | 2.19 | 12.26 | 20.05 | ||
| Short term receivables total | 330.05 | 365.05 | 259.45 | ||
| Cash and bank deposits | 9.10 | 25.04 | 33.77 | ||
| Cash and cash equivalents | 9.10 | 25.04 | 33.77 | ||
| Balance sheet total (assets) | 380.97 | 427.21 | 428.52 | 550.15 | 470.29 |
Equity and liabilities (mDKK)
2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 263.21 | 332.43 | 2.00 | 2.10 | 2.10 |
| Shares repurchased | 90.00 | 150.00 | 119.00 | ||
| Other reserves | 35.69 | -2.34 | -2.61 | ||
| Retained earnings | -22.24 | -83.61 | 127.14 | 80.70 | 81.08 |
| Profit of the financial year | 22.24 | 83.61 | 57.98 | 119.26 | 119.75 |
| Minority interest (BS) | 1.35 | 1.20 | |||
| Shareholders equity total | 263.21 | 332.43 | 312.81 | 351.07 | 320.52 |
| Provisions | 7.21 | 9.65 | |||
| Non-current other liabilities | 7.21 | 9.65 | |||
| Non-current deferred tax liabilities | 1.79 | ||||
| Non-current liabilities total | 1.79 | 7.21 | 9.65 | ||
| Advances received | 33.92 | 104.28 | 76.37 | ||
| Current trade creditors | 53.42 | 56.61 | 25.20 | ||
| Current owed to group member | 0.86 | 4.69 | |||
| Other non-interest bearing current liabilities | 25.72 | 30.97 | 33.86 | ||
| Current liabilities total | 113.92 | 191.87 | 140.12 | ||
| Balance sheet total (liabilities) | 263.21 | 332.43 | 428.52 | 557.37 | 479.95 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
See instructions
... and more!
No registration needed.